相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies
V. T. Ho et al.
BONE MARROW TRANSPLANTATION (2008)
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
Francisco M. Marty et al.
BLOOD (2007)
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
Corey Cutler et al.
BLOOD (2007)
Impaired endothelial vasomotor function after sirolimus-eluting stent implantation
Soichiro Fuke et al.
CIRCULATION JOURNAL (2007)
Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells
Christian M. Matter et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2006)
Influence of glutathione S-transferase A1 polymorphism on the phartnacokinetics of busulfan
Makiko Kusama et al.
CLINICA CHIMICA ACTA (2006)
Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys
H Sartelet et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
C Cutler et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Mucositis after allogeneic hematopoietic stem cell transplantation: A cohort study of methotrexate- and non-methotrexate-containing Graft-versus-host disease prophylaxis regimens
C Cutler et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
M Wadleigh et al.
BLOOD (2003)
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
JH Antin et al.
BLOOD (2003)
Rapamycin: Signaling in vascular smooth muscle
AR Marks
TRANSPLANTATION PROCEEDINGS (2003)
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications
JC Dunkelberg et al.
LIVER TRANSPLANTATION (2003)
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
PG Richardson et al.
BLOOD (2002)
Sirolimus (Rapamune) in renal transplantation
RWG Johnson
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2002)
Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide
JH Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling
R Humar et al.
FASEB JOURNAL (2002)
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality
A Kashyap et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin)
S Bramow et al.
PHARMACOLOGY & TOXICOLOGY (2001)
Orthotopic liver transplantation using low-dose tacrolimus and sirolimus
VC McAlister et al.
LIVER TRANSPLANTATION (2001)
Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation
EA Copelan et al.
BONE MARROW TRANSPLANTATION (2001)
分享论文
